Previous 10 | Next 10 |
ZYNLONTA ® (loncastuximab tesirine-lpyl) net sales of $19.8 million in Q4 2022, +16.5% year-over-year, and $74.9 million for the full year (FY) 2022 FY 2023 ZYNLONTA net sales expected to grow by a double-digit percentage year-over-year Multiple data catalysts expecte...
ADC Therapeutics SA (NYSE: ADCT) today announced that it will host a conference call and live webcast on Tuesday, February 28, 2023 at 8:30 a.m. ET to report financial results for the fourth quarter and year-end 2022 and provide business updates. To access the conference call, please register...
ADC Therapeutics ( NYSE: ADCT ) shares fell over 6% premarket on Thursday after the biotechnology company announced pricing of an underwritten offering of 12M common shares by A.T. Holdings II Sàrl. The shares are being sold at $5.00 each. ADCT is not selling any shar...
ADC Therapeutics SA (“ADCT” or the “Company”) (NYSE: ADCT), a commercial-stage biotechnology company helping to improve the lives of those affected by cancer with its next-generation, targeted antibody drug conjugates, today announced the pricing of an underwritten...
ADC Therapeutics SA (NYSE: ADCT) announced today that Ameet Mallik, Chief Executive Officer, will participate in two investor conferences in February. Details of the events are as follows: Guggenheim Healthcare Talks – Oncology Day, fireside chat on Wednesday, February 8 th f...
Summary FDA and EU approved, the joint therapy Enhertu is set to become a blockbuster. The therapy targets HER-2 cancers and is already expanding indications beyond breast cancer. With this successful antibody-drug conjugate, the entire sub-industry is now seeing renewed momentum he...
IntoCell signed a Material Transfer Agreemen t (or MTA) with option to license with ADC Therapeutics SA ( NYSE: ADCT ). Under the agreement, IntoCell, a South Korean biotech developing novel antibody drug conjugate platform technologies, will provide proprietary drug-link...
ADC Therapeutics SA (NYSE: ADCT) announced today that Ameet Mallik, Chief Executive Officer, will present a company overview at the 41 st Annual J.P. Morgan Healthcare Conference in San Francisco, CA, on Wednesday, January 11 th at 3:00 p.m. PT. A live webcast of the presentation will...
ADC Therapeutics ( NYSE: ADCT ) on Tuesday said it had named Mohamed Zaki as its chief medical officer. Zaki succeeds Joseph Camardo. Zaki joins ADCT from AbbVie ( ABBV ), where he served as VP and global head of oncology development. Prior to ABBV, Zaki spen...
ADC Therapeutics SA (NYSE: ADCT) today announced the appointment of industry veteran Mohamed Zaki, MD, PhD, as Chief Medical Officer (CMO), effective January 3, 2023. He will serve on the Company’s executive leadership team. Dr. Zaki succeeds Joseph Camardo, MD, who is stepping down from f...
News, Short Squeeze, Breakout and More Instantly...
£90m ($114m) series A co-led by new leading life science investors Novo Holdings and Abingworth Additional new investors British Patient Capital, Cancer Research Horizons and Lilly participated alongside founding investors Brandon Capital and Sofinnova Partners Funds will be used to ...
LAUSANNE, Switzerland, June 27, 2024 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (NYSE: ADCT) today announced that the Company is set to join the Russell 2000 ® Index and the broad-market Russell 3000 ® Index at the conclusion of the 2024 Russell US Indexes annual reconstitution, ef...